Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults

Adolescent and adult patients with neuroblastoma appear to have a more indolent disease course but a lower survival rate compared with their younger counterparts. The majority of neuroblastoma tumors specifically accumulate the radiolabeled norepinephrine analogue iodine‐131–metaiodobenzylguanidine (131I‐MIBG). Therefore, 131I‐MIBG has become increasingly used as targeted radiotherapy for patients with recurrent or refractory neuroblastoma. The objective of the current study was to characterize the toxicity and activity of this therapy in older patients.

[1]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[2]  L. Qin,et al.  Differential impact of high‐dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma , 2010, Cancer.

[3]  K. Matthay,et al.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. , 2008, Nuclear medicine and biology.

[4]  S. Idriss,et al.  Case report: an unusual case of adrenal neuroblastoma in pregnancy. , 2008, The oncologist.

[5]  Su-Chun Cheng,et al.  Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[7]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Charron,et al.  Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Caron,et al.  Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  R. Hawkins,et al.  Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma , 2003, Journal of pediatric hematology/oncology.

[11]  C. Gambini,et al.  Second malignancies in children with neuroblastoma after combined treatment with 131I‐metaiodobenzylguanidine , 2003, Cancer.

[12]  K K Matthay,et al.  Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  D. Stram,et al.  Neuroblastoma in adults and adolescents: an indolent course with poor survival. , 1998, Cancer.

[14]  J. Hoehner,et al.  A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[15]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[16]  L. Landsberg,et al.  Neuroblastoma in adults. Three case reports and a review of the literature , 1986, Cancer.

[17]  H. B. Marsden,et al.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. , 1984, Journal of the National Cancer Institute.

[18]  D. Niethammer,et al.  SCINTIGRAPHIC IMAGING OF NEUROBLASTOMA WITH [131I]IODOBENZYLGUANIDINE , 1984, The Lancet.

[19]  C E Koop,et al.  Special pattern of widespread neuroblastoma with a favourable prognosis. , 1971, Lancet.

[20]  B. Hasegawa,et al.  Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Vonkaulla.  LIVER IN REGULATION OF FIBRINOLYTIC ACTIVITY. , 1964, Lancet.